Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18268906 | 0.86 | CA1 (0.50) | LMNACYP2C9ALDH1A1TP53TSHR | |
| SCHEMBL18268915 | 0.86 | CA1 (0.50) | LMNACYP2C9ALDH1A1TP53TSHR | |
| SCHEMBL19484936 | 0.83 | CA1 (0.52) | LMNACYP2C9ALDH1A1TP53TSHR | |
| SCHEMBL7773516 | 0.78 | CA1 (0.52) | LMNACYP2C9ALDH1A1TP53TSHR | |
| SCHEMBL7773530 | 0.78 | CA1 (0.52) | LMNACYP2C9ALDH1A1TP53TSHR | |
| SCHEMBL438928 | 0.78 | — | — | |
| SCHEMBL758910 | 0.78 | — | — | |
| SCHEMBL20159597 | 0.73 | LMNA (0.48) | LMNACYP2C9ALDH1A1TP53TSHR | |
| SCHEMBL31163780 | 0.71 | LMNA (0.46) | LMNACYP2C9ALDH1A1TP53TSHR | |
| SCHEMBL847110 | 0.70 | LMNA (0.43) | LMNACYP2C9ALDH1A1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| WO-2025080689-A1 | LIPID PRODRUGS OF BROMOLYSERGIDE AND USES THEREOF | SEAPORT THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4247817-A1 | MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230099745-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2023-03-30 | — | — | US | disclosed |
| WO-2022109573-A1 | MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-27 | — | — | WO | disclosed |
| US-9951163-B2 | (Meth)acrylate compound, (meth)acrylic copolymer and photosensitive resin composition containing same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-20160347896-A1 | (METH)ACRYLATE COMPOUND, (METH)ACRYLIC COPOLYMER AND PHOTOSENSITIVE RESIN COMPOSITION CONTAINING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2016-12-01 | — | — | US | disclosed |
| US-20160347896-A1 | (METH)ACRYLATE COMPOUND, (METH)ACRYLIC COPOLYMER AND PHOTOSENSITIVE RESIN COMPOSITION CONTAINING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2016-12-01 | — | — | US | disclosed |
| EP-2647656-A2 | Bioresorbable and biocompatible thermoplastic elastomer having a shape memory, particularly for biomedical applications and a process for their preparation | Centrum Materialów Polimerowych i Weglowych PAN (PL) | 2013-10-09 | — | — | EP | disclosed |
| US-20090186991-A1 | METHOD FOR PRODUCING POLYESTER BLOCK COPOLYMERS | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-2022807-A1 | PROCESS FOR PRODUCTION OF POLYESTER BLOCK COPOLYMER | Daicel Chemical Industries, Ltd. (JP) | 2009-02-11 | — | — | EP | disclosed |
| EP-1056716-B1 | CYCLOHEXANEDIOLE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2002-12-11 | — | — | EP | disclosed |
| US-6184422-B1 | TREATMENT AND PREVENTION OF HYPERPROLIFERATIVE SKIN DISEASES; REVERSING CONDITIONS ASSOCIATED WITH PHOTODAMAGE; ANTITUMOR, -CARCINOGENIC AGENTS; PSORIASIS; DISORDERS OF NEOPLASTIC DISEASES; KERATINIZATION/KERATOSIS; ACNE; SEBORRHEA | HOFFMAN-LA ROCHE INC. | 2001-02-06 | — | — | US | disclosed |
| EP-1056716-A1 | CYCLOHEXANEDIOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043646-A1 | CYCLOHEXANEDIOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347896-A1 | (METH)ACRYLATE COMPOUND, (METH)ACRYLIC COPOLYMER AND PHOTOSENSITIVE RESIN COMPOSITION CONTAINING SAME | REV1, EEF1A1, EEF1A2 | LMNA 2187/4885CYP2C9 2717/4885ALDH1A1 1187/4885 |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | LMNA 4099/4885CYP2C9 4781/4885ALDH1A1 3972/4885 |
| US-20230099745-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | LMNA 4099/4885CYP2C9 4781/4885ALDH1A1 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.